{"prompt": "['Product: MK-3475', '5', 'Protocol/Amendment No.: 604-09', '7.1.2.6 Prophylactic Cranial Irradiation', '75', '7.1.2.7 Tumor Imaging and Assessment of Disease', '75', '7.1.2.7.1', 'Initial Tumor Imaging', '76', '7.1.2.7.2', 'Tumor Imaging During the Trial', '76', '7.1.2.7.3', 'End of Treatment and Follow-up of Tumor Imaging', '77', '7.1.2.7.4', 'Second Course (Retreatment) Phase Tumor Imaging', '77', '7.1.2.7.5', 'RECIST 1.1 Assessment of Disease', '78', '7.1.2.7.6 irRECIST Assessment of Disease', '78', '7.1.2.8 Tumor Tissue Collection: PD-L1 Status', '83', '7.1.3 Laboratory Procedures/Assessments', '84', '7.1.3.1', 'Clinical Laboratory Evaluations', '84', '7.1.3.2', 'Pharmacokinetic/Pharmacodynamic Evaluations', '86', '7.1.3.3', 'Planned Genetic Analysis Sample Collection', '87', '7.1.3.4 Future Biomedical Research Samples', '87', '7.1.4', 'Other Procedures', '87', '7.1.4.1 Withdrawal/Discontinuation', '87', '7.1.4.2 Subject Blinding/Unblinding', '88', '7.1.4.3 Calibration of Critical Equipment', '88', '7.1.5 Visit Requirements', '89', '7.1.5.1 Screening', '89', '7.1.5.2', 'Treatment Period Visits', '89', '7.1.5.3', 'Post-treatment Visits', '89', '7.1.5.3.1', 'Safety Follow-up Visit', '89', '7.1.5.3.2', 'Progression-free Survival Follow-up Visits', '90', '7.1.5.3.3', 'Survival Follow-up', '90', '7.1.5.4', 'Survival Status', '90', '7.1.5.5', 'Second Course Phase', '91', '7.1.5.6 Continued Treatment Following Verified Progressive Disease', '92', '7.1.5.7 Discontinued Subjects Continuing to be Monitored in the Trial', '92', '7.2', 'Assessing and Recording Adverse Events', '93', '7.2.1 Definition of an Overdose for This Protocol and Reporting of Overdose to', 'the Sponsor', '94', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '6', 'Protocol/Amendment No.: 604-09', '7.2.2 Reporting of Pregnancy and Lactation to the Sponsor', '94', '7.2.3', 'Immediate Reporting of Adverse Events to the Sponsor', '95', '7.2.3.1', 'Serious Adverse Events', '95', '7.2.3.2', 'Events of Clinical Interest', '96', '7.2.3.3 Protocol-Specific Exceptions to Serious Adverse Event Reporting', '97', '7.2.4 Evaluating Adverse Events', '97', '7.2.5 Sponsor Responsibility for Reporting Adverse Events', '100', '7.3', 'TRIAL GOVERNANCE AND OVERSIGHT', '100', '7.3.1 Data Monitoring Committee', '100', '8.0', 'STATISTICAL ANALYSIS PLAN', '100', '8.1', 'Statistical Analysis Plan Summary', '101', '8.2', 'Responsibility for Analyses/In-house Blinding', '102', '8.3', 'Hypotheses/Estimation', '103', '8.4', 'Analysis Enppoints', '103', '8.4.1', 'Efficacy Endpoints', '103', '8.4.2', 'Safety Endpoints', '104', '8.5', 'Analysis Populations', '104', '8.5.1 Efficacy Analysis Populations', '104', '8.5.2 Safety Analysis Populations', '104', '8.6', 'Statistical Methods', '105', '8.6.1 Statistical Methods for Efficacy Analyses', '105', '8.6.1.1', 'Progression-free Survival', '105', '8.6.1.2', 'Overall Survival', '106', '8.6.1.3', 'Objective Response Rate', '107', '8.6.1.4', 'Duration of Response', '107', '8.6.2', 'Statistical Methods for Safety Analyses', '108', '8.6.3', 'Summaries of Baseline Characteristics and Demographics', '110', '8.7', 'Interim Analyses', '110', '8.8', 'Multiplicity', '110', '8.9', 'Sample Size and Power Calculations', '114', '8.10', 'Subgroup Analyses and Effect of Baseline Factors', '114', '8.11', 'Compliance (Medication Adherence)', '115', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']\n\n###\n\n", "completion": "END"}